Pembrolizumab antitumor efficacy in KEYNOTE-158

Response type	Number of enrolled patients	Objective response rate (%)	Median progression-free survival (months, 95% CI)
Cholangiocarcinoma/biliary tract	22	40.9	4.2 (2.4 to 24.9)
Endometrial	68	48.5	13.1 (4.9 to 34.4)
Gastric	42	31.0	3.2 (2.1 to 12.9)
Ovarian	24	33.3	2.2 (2.0 to 6.2)
Pancreatic	22	18.2	2.1 (1.9 to 3.4)
Small intestine	25	48.0	23.4 (4.3 to "not reached")

Data from: Gaio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022; 33:929.

Graphic 139972 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟